Humalog Mix 50 - instructions for use, dose, side effects, contraindications

Active substanceInsulin lyspro two-phaseInsulin lyspro two-phase

Similar drugsTo uncover

Humalog® Mix 25

suspension PC

Eli Lilly East SA Switzerland

Humalog® Mix 50

suspension PC

Eli Lilly East SA Switzerland

Dosage form: & nbspsubcutaneous suspension

Composition:

In 1 ml contains:

active substance: insulin lyspro 100 ME;

Excipients: metacresol 2.2 mg, phenol liquid 1.0 mg, glycerol (glycerin) 16 mg, protamine sulfate 0.19 mg, sodium hydrogen phosphate heptahydrate 3.78 mg, zinc oxide qs to obtain zinc ions 30.5 μg, water for injection up to 1 ml; 10% hydrochloric acid solution and / or 10% sodium hydroxide solution qs to a pH of 7.0-7.8.

Description:

A white suspension that exfoliates to form a white precipitate and a clear, colorless or almost colorless supernatant. The precipitate is easily resuspended by gentle shaking.

Pharmacotherapeutic group:Hypoglycemic agent is a combination of insulin analogues of short and medium duration of action

ATX: & nbsp

A.10.A.B.04 Insulin LizPro

Pharmacodynamics:

Humalog® Mix 50 is a ready-made mixture consisting of a 50% insulin solution of lyspro (high-speed analog of human insulin) and a protamine insulin suspension of 50% lyspro (an analog of human insulin of average duration of action).

The main effect of insulin lispro is the regulation of glucose metabolism.

In addition, it has anabolic and anti-catabolic effect on various tissues of the body. In muscle tissue, the content of glycogen, fatty acids, glycerol increases, protein synthesis increases and amino acid consumption increases, but glycogenolysis, gluconeogenesis, ketogenesis, lipolysis, protein catabolism and amino acid release decrease.

Shown, that insulin lyspro is equimolar to human insulin, but its effect comes faster and lasts less.

Completeness of absorption and the beginning of the effect of insulin depends on the place of administration (abdomen, thigh, buttocks), the dose (volume of insulin administered), blood supply, body temperature and physical activity.

After a subcutaneous injection of Humalog® Mix 50, a rapid onset of action and an early onset of the peak in insulin activity of lyspro is observed. The beginning of the drug - about 15 minutes, which allows you to enter the drug immediately before meals (0-15 minutes before meals), compared with the usual human insulin. After a subcutaneous injection of Humalog® Mix 50, a rapid onset of action and an early onset of the peak in insulin activity of lyspro is observed.The profile of insulin action of lispro protamine is similar to that of normal insulin-isophane with a duration of about 15 hours.

Pharmacokinetics:

The pharmacokinetics of insulin lispro is characterized by rapid absorption and reaching a maximum concentration in the blood 30-70 minutes after subcutaneous injection. The pharmacokinetics of the insulin suspension of lyspro protamine is similar to that of insulin of average duration of action (insulin-isophane). Pharmacokinetics of the preparation Humalog® Mix 50 is determined by the individual pharmacokinetic properties of the two components of the preparation.

With the introduction of insulin lizpro, faster absorption is observed compared to soluble human insulin in patients with renal insufficiency. In patients with type 2 diabetes mellitus, the pharmacokinetic differences between insulin lispro and soluble human insulin are observed in a wide range of kidney function regardless of renal function. With the introduction of insulin lispro, faster absorption and faster elimination than soluble human insulin in patients with hepatic insufficiency is noted.

Indications:

Diabetes mellitus, requiring insulin therapy.

Contraindications:

- Hypersensitivity to insulin or to one of the components of the drug;

- Hypoglycemia.

The safety and efficacy of Humalog® Mix 50 in patients under 18 years of age has not been studied.

Carefully:

- The period of pregnancy and breastfeeding;

- In case of renal insufficiency, hepatic insufficiency, emotional overstrain, increased physical activity, changes in the usual diet, the need for insulin may change and a correction of the insulin dose may be required;

With long-term diabetes mellitus, diabetic neuropathy or with the use of beta-blockers may change or be less pronounced symptoms-precursors of hypoglycemia.

Pregnancy and lactation:

The results of studies in animals showed no impairment of fertility or a negative effect of insulin fructose on fetus. Controlled clinical studies of the use of insulin lizpro in pregnant women have not been conducted. Since studies of the effect of drugs on reproduction in animals do not always allow extrapolating the effects to the human body,the preparation Humalog® Mix 50 during pregnancy should be used only in case of obvious clinical necessity.

Patients with diabetes are advised to inform the doctor about an impending or planned pregnancy.

During pregnancy it is especially important to monitor the status of patients receiving insulin therapy. The need for insulin usually decreases during the I trimester and increases during II and III trimesters. During and immediately after delivery, the need for insulin can dramatically decrease.

Patients with diabetes mellitus during breastfeeding may need to adjust the dose of insulin, diet, or both.

Dosing and Administration:

Subcutaneously.

The dose of Humalog® Mix 50 is determined by the doctor individually depending on the concentration of blood glucose.

Mode of insulin administration is individual.

The drug should be administered only subcutaneously.

Intravenous administration of Humalog® Mix 50.

The temperature of the drug should be at room temperature.

Subcutaneous injections should be done in the area of the shoulder, hips, buttocks or abdomen.The injection sites need to be alternated so that the same place is used no more often than once a month. When subcutaneous administration of the preparation Humalog® Mix 50, care should be taken to avoid getting the drug into the lumen of blood vessels. After injection, do not massage the injection site.

Recommendations for installing the cartridge in the device for administering Humalog® Mix 50 and attaching the needle to the preparation before the introduction of the preparation are described in the manufacturer's instructions for an insulin delivery device. Strictly follow the instructions given.

After the subcutaneous administration of Humalog® Mix 50, a rapid onset of action and an early peak in the activity of insulin lispro is observed. Due to this, Humalog® Mix 50 can be administered immediately before or after a meal. The duration of action of the insulin suspension of lispro-protamine, which is part of Humalog® Mix 50. is similar to the duration of insulin-isophane.

The profile of the action of insulin, regardless of its type, is subject to significant fluctuations, both in different patients depending on their individual characteristics, and in one patient, depending on the specific time.As with any other insulin preparation, the duration of the Humalog® Mix 50 preparation depends on the dose, the injection site, the blood supply, body temperature and physical activity.

Preparations for introduction

Immediately before use, the Humalog® Mix 50 cartridge should be rolled between the palms ten times and shaken, turning 180 ° also ten times to resuspend insulin until it looks like a homogeneous turbid liquid. Do not shake vigorously, as this can lead to the appearance of foam, which may interfere with the correct dose set. To facilitate mixing, there is a small glass ball inside the cartridge.

Do not use Humalog® Mix 50 if flakes are present after mixing.

Dosing Introduction

1. Wash your hands.

2. Choose a place for injection.

3. Prepare the skin at the injection site in accordance with the physician's recommendations.

4. Remove the outer protective cap from the needle.

5. Fix the skin, collecting it in a large crease.

6. Insert the needle subcutaneously into the collected fold and perform the injection according to the instructions for using the syringe pen.

7. Remove the needle and gently squeeze the injection site with a cotton swab for a few seconds. Do not rub the injection site.

8. Using the outer protective cap of the needle, unscrew the needle and dispose of it.

9. Put the cap on the syringe pen.

For the preparation Humalog^® Mix 50 in the syringe pen QuickKenny™

Before the introduction of insulin, it is necessary to familiarize yourself with the Guidelines for the use of the KvikPen syringe pen™.

Side effects:

Hypoglycaemia is the most common side effect that occurs with the administration of all insulin preparations, including Humalog® Mix 50. Severe hypoglycemia can lead to loss of consciousness and. in exceptional cases, to death.

Allergic reactions: patients may experience local allergic reactions in the form of redness, swelling, or itching at the injection site. These minor reactions usually disappear within a few days or weeks. In a number of cases, these reactions can be caused by causes not associated with insulin, for example, skin irritation with a cleansing agent or with improper injection.

Systemic allergic reactions, caused by insulin, are less common, but are more serious.They can manifest generalized itching, difficulty breathing, shortness of breath, lower blood pressure, tachycardia, increased sweating. Severe cases of systemic allergic reactions can be life threatening. In rare cases, a severe allergy to Humalog® Mix 50 requires immediate treatment. It may be necessary to change insulin, or conduct desensitization.

With prolonged use, it is possible to develop lipodystrophy at the injection site.

Spontaneous messages

There were cases of edema development, mainly with fast normalization of blood glucose concentration against intensive insulin therapy with initially unsatisfactory glycemic control.

Overdose:

An overdose of insulin causes hypoglycemia, followed by the following symptoms: lethargy, increased sweating, tachycardia, pallor of the skin, headache, trembling, vomiting, confusion. Under certain conditions, for example, with a long duration of the disease or with intensive control of diabetes mellitus, the symptoms-precursors of hypoglycemia may change.

Light states of hypoglycemia can usually be suppressed by ingestion of glucose or sugar. You may need to adjust the dose of insulin, diet or physical activity. Correction of hypoglycemia of moderate severity can be carried out by intramuscular or subcutaneous administration of glucagon, followed by ingestion of carbohydrates.

Severe hypoglycemia, accompanied by coma, convulsions or neurological disorders, is stopped by intramuscular / subcutaneous administration of glucagon or by intravenous administration of a concentrated solution of dextrose (glucose). After restoring consciousness, the patient should be given food rich in carbohydrates, in order to avoid the re-development of hypoglycemia. It may be necessary to take further carbohydrates and follow up the patient, since there may be a relapse of hypoglycemia.

Interaction:

The hypoglycemic effect of Humalog® Mix 50 decreases when co-administered with the following drugs: oral contraceptives, glucocorticosteroids, iodine-containing thyroid hormones, danazol, beta₂-adrenomimetics (for example, ritodrin, salbutamol, terbutaline), thiazide diuretics, chloroprotoxen, diazoxide, isoniazid, a nicotinic acid, phenothiazine derivatives.

The hypoglycemic effect of Humalog® Mix 50 increases: beta-blockers, ethanol and ethanol containing drugs, anabolic steroids, fenfluramine, guanethidine, tetracyclines, oral hypoglycemic drugs, salicylates (for example, acetylsalicylic acid), sulfonamide antibiotics, some antidepressants (monoamine oxidase inhibitors), angiotensin converting enzyme inhibitors (captopril, enapril), octreotide, angiotensin II receptor antagonists.

Beta-adrenoblockers, clonidine, reserpine can mask the manifestation of symptoms of hypoglycemia.

The interaction of Humalog® Mix 50 with other insulin preparations has not been studied.

If you need to use other medications in addition to insulin, you should consult your doctor.

The simultaneous use of Humalog® Mix 50 with thiazolidinedione may increase the risk of edema and heart failure, especially in patients with cardiovascular disease.

Special instructions:

Transfer of the patient to another type or preparation of insulin with a different trade name should occur under strict medical supervision. Change in activity, brand (manufacturer), type (insulin soluble, insulin-isophane, etc.). species (animal, human, human insulin analog) and / or production method (DNA-recombinant insulin or animal-derived insulin) may lead to the need for dose adjustment.

In some patients, when switching from animal insulin to human insulin, it may be necessary to adjust the dose. This can happen even with the first injection of a human insulin preparation or gradually for several weeks or months after the transfer.

Unadjusted hypoglycemic or hyperglycemic conditions can cause loss of consciousness, to whom or death. Symptoms-precursors of hypoglycemia may change or be less pronounced with prolonged course of diabetes mellitus, diabetic neuropathy, or treatment with drugs such as beta-blockers.

The use of inadequate doses or discontinuation of treatment, especially in patients with type 1 diabetes, can lead to hyperglycemia and diabetic ketoacidosis (potentially potentially life-threatening conditions).

The need for insulin may decrease with renal insufficiency, as well as in liver failure due to a decrease in the ability to gluconeogenesis and reduce the metabolism of insulin, but in patients with chronic hepatic insufficiency, increased insulin resistance may lead to an increase in the need for it.

The need for insulin can increase with certain diseases or with emotional overstrain.

Correction of the dose of insulin may be required with an increase in physical activity or with a change in the usual diet. Physical stress can lead to an increased risk of developing hypoglycemia.

When using insulin preparations in combination with drugs of the thiazolidinedione group, the risk of edema and chronic heart failure increases, especially in patients with cardiovascular disease and the presence of risk factors for chronic heart failure.

To avoid possible transmission of an infectious disease, each cartridge / syringe pen should be used by only one patient, even if the needle is replaced. Cartridges with Humalog® Mix 50 should be used with CE-marked syringes in accordance with the manufacturer's instructions.

GUIDE FOR USING THE SYRINGE-HANDLE QuickKenny ™

Humalog® QuickPan ™, Humalog® Mix 25 QuickPan ™, Humalog® Mix 50 QuickPan ™

100 IU / ml, 3 ml

PLEASE READ THESE INSTRUCTIONS BEFORE APPLICATION

Introduction

Syringe pen QuickKenny easy to use. It is a device for the introduction of insulin (an "insulin syringe pen") containing 3 ml (300 units) of an insulin preparation with an activity of 100 IU / ml. You can administer 1 to 60 units of insulin per injection. You can set the dose to within one unit. If you have set too many units. You can correct the dose without losing insulin.

Before using the QuickKP pen, read this manual completely and follow its instructions carefully. If you do not fully comply with these instructions, then you can get either too low or too high a dose of insulin.

Your syringe Penkin Pen for insulin administration should only be used for your injections.Do not pass the syringe pen or needle to others, as this can lead to transmission of the infection. For each injection, use a new needle.

DO NOT USE a syringe pen if any of its parts is damaged or broken. Always have a spare syringe-pen in case you lose a syringe pen or it will be damaged.

It is not recommended to use a syringe pen for patients with complete loss of sight or with impaired vision without the help of well-seeing people trained in the use of a syringe pen.

Preparing the QuickK pen

Important notes

- Read and follow the instructions for use described in the Instructions for Use.

- Check the label on the syringe pen before each injection to make sure the drug has not expired and you are using the right type of insulin; Do not remove the label from the syringe pen.

Note: Color of the dose button of the syringe-pen QuickKenny corresponds to the color of the strip on the label of the syringe pen and depends on the type of insulin. In this manual, the dose button is grayed out. Blue color of syringe-pen body QuickKenny indicates that it is intended for use with preparations of the Humalog line.

Color marking of the dose introduction button.

- Your doctor wrote you the most suitable type of insulin. Any changes in insulin therapy should be performed only under the supervision of the attending physician.

- The QUIKPEN syringe is recommended to be used with needles from Becton, Dickinson and Company (BD) for pen syringes.

- Before using the syringe pen, make sure that the needle is fully attached to the syringe pen.

- Follow the instructions given here.

Frequently Asked Questions about preparing a QUIKPEN pen syringe for use

- What should my insulin look like? Some insulin preparations are cloudy suspensions, while others are clear solutions; be sure to read the description of insulin in the enclosed Instruction for Use.

- What should I do if the dose prescribed to me is more than 60 units? If your dose is more than 60 units, you will need a second injection, or you can contact the doctor in charge.

- Why should I use a new needle for each injection? If the needles are reused, you may receive an incorrect dose of insulin, the needle may become clogged, or the syringe pen will start to seize, or you may infect the infection due to a sterility violation.

- What should I do if I'm not sure how much insulin is left in my cartridge? Take the handle so that the tip of the needle is pointing down. The scale on the transparent cartridge holder shows the approximate number of remaining insulin units. These numbers MUST NOT be used to set the dose.

- What should I do if I can not remove the cap from the syringe pen? For To remove the cap, pull it. If you are having difficulty removing the cap, gently turn the cap clockwise and counterclockwise to release it, then pull it off, remove the cap.

Checking the QUIKPEN syringe pen for insulin delivery

Important notes:

- Check insulin intake every time. Checking the intake of insulin from the syringe-pen should be performed before each injection before the emergence of a trickle of insulin to make sure that the syringe pen is ready for the dose.

- If you do not check the insulin intake before the trickle, you can get too little or too much insulin.

Frequently asked questions about insulin intake check

- Why should I check the insulin intake before each injection?

1. This ensures that the syringe pen is ready for the dose.

2. This confirms that the trickle of insulin exits the needle when you press the dose button.

3. This removes air that can collect in the needle or in the cartridge with insulin during normal use.

- What should I do if I can not fully press the dose input button while checking QuickPen on insulin delivery?

1. Attach a new needle.

2. Inspect the insulin intake from the syringe pen.

- What should I do if I see air bubbles in the cartridge?

You must check the insulin intake from the syringe pen. Remember that you can not store a syringe pen with a needle attached to it, as this can lead to the formation of air bubbles in the cartridge with insulin. A small air bubble does not affect the dose, and you can enter your dose as usual.

Administration of the required dose

Important notes:

- Observe the rules of asepsis and antiseptics, recommended by the attending physician.

- Make sure that you have entered the desired dose by pressing and holding the dose button, and slowly count to 5 before removing the needle. If the insulin drips from the needle, most likely, you did not hold the needle under the skin long enough.

- The presence of a drop of insulin at the tip of the needle - this is normal. This will not affect your dose.

- The syringe pen will not allow you to dial a dose exceeding the number of units of insulin left in the cartridge.

- If you doubt that you have taken the full dose, do not administer another dose. Call the Lilly office or ask your doctor for help.

- If your dose exceeds the number of units left in the cartridge, you can enter the remaining amount of insulin in this syringe pen and then use a new pen to complete the required dose, OR EVERYTHING the whole dose you need using a new syringe pen.

- Do not attempt to inject insulin by rotation dose introduction buttons. You will NOT get insulin if you turn the dose button. You must PUT on the dose button on a straight axis in order to get a dose of insulin.

- Do not try to change the dose of insulin during the injection.

- The used needle should be disposed of in accordance with local medical waste disposal requirements.

- Remove the needle after each injection.

Frequently Asked Questions for Dose Administration

- Why is it difficult to press the dose button, the cord I try to inject?

1. Your needle may be clogged. Attempt to attach a new needle. Once you do this, you can see how the insulin exits the needle. Then, check the syringe pen for insulin.

2. A quick push of a dose button may make pressing a button hard. A slower depression of the dose button may make pressing easier.

3. Using a larger diameter needle will make it easier to press the dose button during the injection.

Consult your doctor to determine the size of the needle you are most likely to use.

4. If the button is pressed hard when the dose is applied, after tightening all the above points, the syringe pen must be replaced.

- What should I do if the syringe pen QuickKenny seizes when used?

Your syringe stickles up if it is difficult to inject or set a dose. In order for the syringe pen to not seize:

1. Attach a new needle. Once you do this, you can see how the insulin exits the needle.

2. Inspect your insulin intake.

3. Set the dose and inject.

Do not attempt to lubricate the syringe handle, as this may damage the mechanism of the syringe handle.

Pressing the button to enter the dose can become taut if foreign impurities (dirt, dust, food, insulin or any liquids) get inside the syringe pen. Do not allow foreign matter to enter the syringe handle.

- Why does insulin leak out of the needle after I have finished administering my dose?

You probably took the needle out of the skin too quickly.

1. Make sure that you see the number "0" in the dose indicator window.

2. To administer the next dose press and hold dose button and slowly count up to 5 before removing the needle.

- What should I do if my dose is set, and the dose button accidentally found to be drowned in without a needle attached to the syringe-pen?

1. Turn the dose button back to zero.

2. Attach a new needle.

3. Inspect your insulin intake.

4. Set the dose and perform the injection.

- What should I do if I have set the wrong dose (too low or too high)? Turn the dose button back or forward to correct the dose.

- What should I do if I see that the insulin is flowing out of the needle of the syringe-pen during the selection or correction of the dose? Do not administer a dose, as you may not receive your full dose. Set the syringe pen to the number zero and again check the insulin intake from the syringe pen (see "Checking the QUIKPEN syringe pen for insulin delivery"). Set the dose and inject.

- What should I do if my full dose can not be established? The syringe pen will not allow you to set a dose that exceeds the number of units of insulin left in the cartridge. For example, if you need 31 units, and only 25 units remain in the cartridge, you can not go through the figure at the time of installation. Do not try to set the dose by going through this figure. If the partial dose is left in the syringe pen, then you can either:

1. Enter this partial dose, and then enter the remaining dose using a new syringe pen, or

2. Enter the full dose from a new pen.

- Why can not I set a dose to use the small amount of insulin that is left in my cartridge? The syringe pen is designed to provide at least 300 insulin units. The device of the syringe-pen protects the cartridge from complete emptying, since the small amount of insulin that remains in the cartridge can not be entered with the necessary accuracy.

Storage and disposal

Important notes:

- The syringe pen can not be used if it is outside the refrigerator for more time specified in the Instruction for Use.

- Do not store a syringe pen with a needle attached to it. If the needle is left attached, insulin can leak out of the pen syringe, or insulin may dry up inside the needle, causing clogging of the needle, or air bubbles may form inside the cartridge.

- Syringe pens that are not in use should be stored in the refrigerator at a temperature of 2 ° C to 8 ° C. Do not use a syringe pen if it has been frozen.

- The syringe pen you are currently using should be stored at a temperature not exceeding 30 ° C and in a place protected from heat and light.

- Refer to the instructions for use to fully understand the storage conditions of the syringe pen.

- Keep the syringe pen out of the reach of children.

- Dispose of used needles in puncture-resistant, sealed containers (for example, in containers for biohazardous substances or waste), or as recommended by your doctor.

- Dispose of used syringes without needles attached to them and in accordance with the advice of your doctor.

- Do not recycle the filled container for sharp objects.

- Ask your health care provider about possible ways to dispose of the filled sharps containers that are available in your area.

- Recommendations for handling needles do not replace local rules for disposal, rules recommended by the attending physician or departmental requirements.

Humalog®, Humalog® in a syringe pen QuickKn ™, Humalog® Mix 50 in the syringe pen QuickKn ™, Humalog® Mix 25 in the syringe pen QuickKenny ™ are trademarks of Eli Lilly and Company.

Date of approval:

The QUIKPEN ™ syringe pen meets the requirements of precise dosing and the functional requirements of ISO 11608 1: 2000

Preparation

Make sure that you have the following components:

□ Syringe handle

□ New needle for syringe pen

□ A swab moistened with alcohol

Components of the pen-syringe QuickKenny and needles * (* sold separately); parts of the syringe-pen.

Common use of the syringe pen

Follow these instructions to complete each injection.

1.Preparation of pen syringes

Pull the cap of the syringe pen to remove it. Do not rotate the cap. Do not remove the label from the syringe pen.

Be sure that you have checked your insulin on:

- Type of insulin

- Expiration date

- Appearance

Attention: Always read the text on the label of the syringe pen to make sure that you are using the right type of insulin.

Only for insulin suspensions:

Carefully roll the syringe pen 10 times between the palms and turn the syringe handle 10 times.

Stirring is important in order to be sure of getting the right dose. Insulin should look uniformly mixed.

AT.

Take a new needle.

Remove the paper sticker from the outer needle cap.

Use a tampon moistened with alcohol to wipe the rubber disc on the end of the cartridge holder.

Put the needle in the cap, straight on the axis on the syringe-pen.

Screw the needle until the connection is complete.

2. Checking the QUIKPEN syringe pen for insulin delivery

Attention: If you do not check the insulin intake before each injection, you can get either too low or too high a dose of insulin.

Remove the outer needle cap. Do not throw it away.

Remove the inner needle cap and discard it.

Set 2 units by rotating the insertion button dose.

AT.

Point the syringe up.

Tap on the cartridge holder to let the air top part.

- By sending the needle up, press the dose button until it stops and the dose indicator appears in the indicator window "0".

- Keep the dose button in the recessed position and count slowly until 5.

- An insulin intake check is considered complete when an insulin stream appears on the end of the needle.

- If a trickle of insulin does not appear at the end of the needle, then repeat the steps of checking insulin intake four times, starting at point 2B and ending at point 2G.

Note: If you do not see the emergence from the needle of a trickle of insulin, and the dose setting becomes difficult, then replace the needle and repeat the insulin intake from the syringe pen.

3. Dosing Introduction

Turn the dose button until the number of units you need for injection.

If you accidentally set too many units, you can correct the dose by rotating the dose button in the opposite direction.

Insert the needle under the skin using the injection technique recommended by your doctor.

Put your thumb on the dose introduction button and firmly press the dose introduction button until it stops completely.

To enter the full dose, hold the dose button and slowly count to 5.

Remove the needle from under the skin.

Note: Check and make sure that you see the number "0" in the dose indicator window, in order to confirm that you have entered the full dose.

AT.

Carefully place the outer cap on the needle.

Note: Remove the needle after each injection to prevent air bubbles from entering the cartridge.

Do not store a syringe pen with a needle attached to it.

Unscrew the needle with the outer cap on it and dispose of in according to the instructions of the attending physician.

Put the cap on the syringe-pen, combining the cap of the cap with the dose indicator, pushing the cap straight on the axis to the syringe-pen.

Example:

15 units are shown.

HThe the numbers are printed in the dose indicator window in the form of numbers, nechThe numbers are printed as straight lines between even ones.

Note: The syringe pen will not allow you to set the number of units greater than the number of units left in the syringe pen.

If you are not sure that you have entered the full dose, do not enter another dose.

Effect on the ability to drive transp. cf. and fur:

During hypoglycemia, the patient's concentration and speed of psychomotor reactions may decrease. This can be dangerous in situations in which these abilities are particularly necessary (for example, driving vehicles or machinery).

Patients should be advised to take precautions to avoid hypoglycemia during the management of vehicles and mechanisms. This is especially important for patients with mild or absent symptoms-precursors of hypoglycemia or with frequent development of hypoglycemia.In such cases, the doctor should evaluate the appropriateness of patient management of vehicles and mechanisms.

Form release / dosage:Suspension for subcutaneous administration, 100 IU / ml.

Packaging:

Cartridges:

3 ml of the drug in the cartridge. Five cartridges per blister. One blister with instructions for use in a cardboard package.

Syringe handle QuickKenny^tm:

By 3 ml of the drug in the cartridge, built in the pen-handle KvikPen^tm. Five five-ply handles^tm together with the instruction manual and the manual for the use of the QUIKPEN pen syringe^tm in a pack of cardboard.

Storage conditions:

At a temperature of 2-8 ° C. Keep away from direct sunlight and heat. Do not freeze.

The drug should be stored at a temperature of no higher than 30 ° C for up to 28 days.

Keep out of the reach of children.

Shelf life:

3 years.

Do not use after the expiration date.

Terms of leave from pharmacies:On prescription

Registration number:LP-001045

Date of registration:21.10.2011

Expiration Date:Unlimited

The owner of the registration certificate:Eli Lilly East SAEli Lilly East SA Switzerland